Vioxx Pediatric Arthritis Indication Could Drive Parents Away From OTCs
This article was originally published in The Tan Sheet
Executive Summary
The recent approval of Merck's Vioxx (rofecoxib) for treatment of juvenile rheumatoid arthritis (JRA) could impact off-label pediatric use of OTC non-steroidal anti-inflammatory drugs